Zobrazeno 1 - 10 of 117 pro vyhledávání: '"G Clamon"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B
Autor: G, Clamon, J, Herndon, W, Akerley, M, Green
Publikováno v: Lung cancer (Amsterdam, Netherlands). 19(1)
In a prior Cancer and Leukemia Group B (CALGB), 16% of a small cohort of patients with extensive small call lung cancer who had failed to obtain a complete remission with chemotherapy did obtain a complete remission after therapy with interleukin-2 (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c1847af525aa3bbeb00f84fb0708ce38
https://pubmed.ncbi.nlm.nih.gov/9493137
Zobrazit plný text záznamu
3
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer
Autor: J Hohneker, J H Schiller, A Koletsky, M O'Rourke, C H Spiridonitis, Ralph W deVere White, C H Spiridonidis, L Hutchins, H Ozer, S Yanovich, A Langleben, S Burman, Jeffrey Crawford, G Clamon
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(10)
PURPOSE This prospective randomized trial was performed to compare the effectiveness of intravenous vinorelbine tartrate with intravenous fluorouracil and leucovorin (5-FU/LV) on the primary end points of survival, quality of life (QOL), and relief o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf44361a1751f33e3013956f430f3ef5
https://pubmed.ncbi.nlm.nih.gov/8874320
Zobrazit plný text záznamu
5
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Autor: G. Clamon, J. Arnott, Alison L. Hannah, H. West, S. Marcotte, Nasser H. Hanna, T. Hoang, C. Sidor, D. Estes
Publikováno v: Journal of Clinical Oncology. 27:e19005-e19005
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi-drug resistant lines, and single agent activity in NSCLC pts. Binding targets of MKC-1 include microtubules, members of t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc9a6c1e0aba9fee87f261a963810938
https://doi.org/10.1200/jco.2009.27.15_suppl.e19005
Zobrazit plný text záznamu
6
Phase 1/2 trial of MKC-1 and pemetrexed in patients (pts) with advanced NSCLC
Autor: G. Clamon, S. Marcotte, Nasser H. Hanna, C. Sidor, J. Arnott, D. Estes, Alison L. Hannah, H. West, T. Hoang
Publikováno v: Journal of Clinical Oncology. 26:19052-19052
19052 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines, including NSCLC and multi-drug resistant cell lines and single agent a...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81628eeab9bb8f668476527b056c3c9c
https://doi.org/10.1200/jco.2008.26.15_suppl.19052
Zobrazit plný text záznamu
7
Targeted radiopharmaceutical therapy for advanced lung cancer: Phase I trial of rhenium Re188 somatostatin analogue P2045
Autor: B. R. Line, M. Magram, Daniel Kahn, G. Clamon, Martin J. Edelman
Publikováno v: Journal of Clinical Oncology. 25:7672-7672
7672 Background: Both small cell (SCLC) and non-small cell lung cancer (NSCLC) overexpress somatostatin receptors (SSTR). P2045 peptide is an 11-amino acid somatostatin analogue that binds with high affinity to SSTR. The analogue can be labeled with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75e7832c42e001e865ec536b1bae0071
https://doi.org/10.1200/jco.2007.25.18_suppl.7672
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Phase 2 Trial of Streptozotocin by Continuous Infusion for Metastatic Colorectal Carcinoma
Autor: G. Clamon, L. Stegink, M. Traves, C. Riggs
Publikováno v: Cancer Drug Delivery. 4:43-46
Streptozotocin is a nitrosourea with minimal activity against colorectal carcinoma when given by bolus administration. Continuous infusion (CI) streptozotocin has been reportedly less toxic. Twenty-six patients with widely advanced colorectal carcino
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144ff871630944c17c65aa7c800f7ec6
https://doi.org/10.1089/cdd.1987.4.43
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje